Credit Suisse’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-61,577
| Closed | -$26K | – | 4273 |
|
|
2018
Q4 | $26K | Buy |
+61,577
| New | +$38.3K | ﹤0.01% | 3831 |
|
|
2016
Q3 | – | Sell |
-16,069
| Closed | -$72K | – | 4387 |
|
|
2016
Q2 | $72K | Buy |
16,069
+14,691
| +1,066% | +$95.9K | ﹤0.01% | 4113 |
|
|
2016
Q1 | $14K | Sell |
1,378
-2,569
| -65% | -$51.1K | ﹤0.01% | 3935 |
|
|
2015
Q4 | $116K | Buy |
3,947
+2,525
| +178% | +$76.4K | ﹤0.01% | 4055 |
|
|
2015
Q3 | $45K | Sell |
1,422
-25,287
| -95% | -$1.21M | ﹤0.01% | 4185 |
|
|
2015
Q2 | $1.58M | Buy |
26,709
+20,328
| +319% | +$1.43M | ﹤0.01% | 2752 |
|
|
2015
Q1 | $682K | Sell |
6,381
-4,768
| -43% | -$454K | ﹤0.01% | 3308 |
|
|
2014
Q4 | $1.05M | Buy |
11,149
+6,275
| +129% | +$599K | ﹤0.01% | 3100 |
|
|
2014
Q3 | $374K | Buy |
4,874
+2,262
| +87% | +$178K | ﹤0.01% | 3816 |
|
|
2014
Q2 | $234K | Buy |
2,612
+1,082
| +71% | +$66.3K | ﹤0.01% | 4264 |
|
|
2014
Q1 | $81K | Buy |
1,530
+448
| +41% | +$14.8K | ﹤0.01% | 4540 |
|
|
2013
Q4 | $27K | Sell |
1,082
-346
| -24% | -$8.24K | ﹤0.01% | 4553 |
|
|
2013
Q3 | $39K | Buy |
+1,428
| New | +$46K | ﹤0.01% | 4159 |
|
Credit Suisse's PTX Position: Q1 2019 in Review
Credit Suisse sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 61,577 shares — an estimated $26K sold.
Credit Suisse first reported a position in PTX in Q3 2013 and held it in 13 quarters. The position peaked at $1.58M in Q2 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- Credit Suisse reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- Credit Suisse sold 61,577 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $26K.
- Credit Suisse first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2013 and held it in 13 quarters.
- Credit Suisse's Pernix Therapeutics Holdings, Inc. position peaked at $1.58M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on Credit Suisse's 13F filing for Q1 2019, filed 14 May 2019.